Onyx Pharmaceuticals Announces Webcast to Discuss Multiple Myeloma Market and Carfilzomib Clinical Overview
October 12 2009 - 8:00AM
PR Newswire (US)
Webcast to Take Place at 11:00 a.m. ET Today, October 12
EMERYVILLE, Calif., Oct. 12 /PRNewswire-FirstCall/ -- Onyx
Pharmaceuticals, Inc. (NASDAQ:ONXX) today announced that it will
host a webcast, led by external medical experts, to discuss the
multiple myeloma market and provide an overview of the carfilzomib
clinical program. The webcast will take place today at 11:00 a.m.
ET, and can be accessed at
http://www.onyx-pharm.com/view.cfm/32/Event-Calendar. The event
follows the announcement of Onyx's intention to acquire Proteolix,
Inc., a privately held biopharmaceutical company focused on
discovering and developing novel therapies that target the
proteasome for the treatment of hematological malignancies and
solid tumors. Proteolix's lead compound, carfilzomib, is a next
generation proteasome inhibitor that is currently in multiple
clinical trials, including an advanced Phase 2b clinical trial for
patients with relapsed and refractory multiple myeloma. About Onyx
Pharmaceuticals, Inc. Onyx Pharmaceuticals, Inc. is a
biopharmaceutical company committed to improving the lives of
people with cancer. The company, in collaboration with Bayer
HealthCare Pharmaceuticals, Inc., is developing and marketing
Nexavar®, a small molecule drug. Nexavar is currently approved for
the treatment of liver cancer and advanced kidney cancer.
Additionally, Nexavar is being investigated in several ongoing
trials in a variety of tumor types. For more information about
Onyx, visit the company's website at http://www.onyx-pharm.com/.
Nexavar® (sorafenib) tablets is a registered trademark of Bayer
HealthCare Pharmaceuticals. DATASOURCE: Onyx Pharmaceuticals, Inc.
CONTACT: Alex Santos, +1-510-597-6504, for Onyx Pharmaceuticals,
Inc. Web Site: http://www.onyx-pharm.com/
Copyright